Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
10 November 2023 - 12:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, obesity and non-alcoholic
steatohepatitis (NASH), today announced that members of management
will be participating in the following upcoming investor
conferences in November.
Jefferies London Healthcare
ConferenceDate/Time: Wednesday, November 15, 2023 at 9:30
a.m. GMTLocation: London, UK
6th
Annual Evercore ISI HealthCONx
ConferenceDate/Time: Wednesday, November 29, 2023 at 1:45
p.m. ETLocation: Miami, FL
Live webcasts of the events will be available on
the investor relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcasts will be
archived on Terns’ website for at least 30 days following the
presentations.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, obesity and NASH.
Terns’ pipeline includes three clinical stage development programs
including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1
receptor agonist, and a THR-β agonist, and a preclinical GIPR
modulator program. For more information, please visit:
www.ternspharma.com.
Contacts for Terns
InvestorsJustin
Nginvestors@ternspharma.com
MediaJenna UrbanBerry &
Company Public Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Jul 2023 to Jul 2024